Anh CX et al., 2020-02-21: Open-label randomised crossover pharmacokinetic study in 15 healthy Vietnamese volunteers given a single oral dose of artesunate-amodiaquine with or without 325 mg methylene blue. MB raised dihydroartemisinin exposure and roughly doubled ex vivo killing of artemisinin-sensitive and artemisinin-resistant parasites.
MB significantly enhanced the blood schizontocidal activity of ASAQ by 2.0-fold and 1.9-fold, respectively.
Abstract
Anh CX et al., 2020-02-21: Open-label randomised crossover pharmacokinetic study in 15 healthy Vietnamese volunteers given a single oral dose of artesunate-amodiaquine with or without 325 mg methylene blue. MB raised dihydroartemisinin exposure and roughly doubled ex vivo killing of artemisinin-sensitive and artemisinin-resistant parasites. Study type: open-label randomised crossover pharmacokinetic study in healthy volunteers (not patients). N=15 adults, Vietnam. Single oral dose ASAQ (200 mg artesunate/540 mg amodiaquine) with or without MB 325 mg. Comparator: same regimen without MB. Outcomes: PK to 28 days and ex vivo activity against P. falciparum MRA1239 (sensitive) and MRA1240 (artemisinin-resistant); ring-stage survival assay 2.9-3.8-fold enhancement. Funder/COI not stated in retrieved abstract record; authors are Australian Army Malaria Institute / military clinical pharmacology collaborators. Study type: randomized trial.
